Top 10 AMCP Sessions Health Execs Should Attend

April 11, 2018
Aubrey Westgate
Aubrey Westgate

Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.

Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations. 

 

 

It’s not easy to keep track of new and developing medications. This pipeline session will help by focusing on new and emerging specialty medications and exploring their likely role in therapy.

 

 

 

Oncology treatment and delivery is changing rapidly, and it’s critical to stay on top of the trends. This session will update you on the latest delivery model changes.

 

 

 

The high number of RA treatments, and costs associated with many of them, make managing these medications properly a top priority.  This session will share tools to help measure the value of RA treatments and how to use those tools to inform cost and utilization management strategies.

 

 

 

 

Gene therapy present great promise, but they also come at a heavy cost. This session will provide you with insight into the budget implications, and how to prepare.

 

 

 

Having trouble keeping track of all the latest treatment developments in oncology? This session will help.  It will review advances in cancer care and provide a health plan’s approach to managing these therapies.

 

 

 

What’s going on in the Alzheimer’s space? This session will explore the drug pipeline, and the potential cost implications.

 

 

 

New players are entering the healthcare system and having a big impact. This session will explore these new players and new innovations from established ones, and the evolving role pharmacists play in optimizing patient outcomes.

 

 

 

Orphan drugs, and the growing number of approvals, has great potential for patients. But these medications also raising significant cost challenges. This article will provide an overview of management strategies.

 

 

 

The industry is bussing about value-based agreements (VBAs), but how common are they really and how often will they be used in the future? This session will provide some insight.

 

 

Legislation regarding biosimilars, from the FDA and at the state-level, continues to be updated. This session will explore the regulations you should be watching.